Published in Radiographics on October 01, 2011
Modern brain tumor imaging. Brain Tumor Res Treat (2015) 0.97
Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma. J Exp Clin Cancer Res (2014) 0.90
Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival. Neuro Oncol (2015) 0.89
Imaging-based observational databases for clinical problem solving: the role of informatics. J Am Med Inform Assoc (2013) 0.78
Simultaneous discovery of bifrontal meningiomas and a glioblastoma multiforme. BMJ Case Rep (2014) 0.75
Diagnostic delay and prognosis in primary central nervous system lymphoma compared with glioblastoma multiforme. Neurol Sci (2015) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Malignant gliomas in adults. N Engl J Med (2008) 20.54
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 14.15
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (1993) 13.68
Tumor angiogenesis. N Engl J Med (2008) 11.30
Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol (2003) 10.29
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology (2008) 8.10
Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin (2010) 5.53
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res (2000) 4.79
CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res (1996) 4.42
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A (2008) 4.14
Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res (1991) 3.16
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res (2009) 3.00
MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol (2005) 2.70
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol (2009) 2.65
Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology (2009) 2.55
Life and death by death receptors. FASEB J (2009) 2.39
CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res (1994) 2.28
Caspases: pharmacological manipulation of cell death. J Clin Invest (2005) 2.10
Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol (2009) 2.08
Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest (2004) 2.02
Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer (2010) 1.87
Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol (1992) 1.78
Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol (2010) 1.63
Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology (2008) 1.58
Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res (2001) 1.58
Understanding the biology of angiogenesis: review of the most important molecular mechanisms. Blood Cells Mol Dis (2007) 1.55
A survey of glioblastoma genomic amplifications and deletions. J Neurooncol (2009) 1.52
Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res (1994) 1.51
Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev (2010) 1.49
Radiographic patterns of relapse in glioblastoma. J Neurooncol (2010) 1.47
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo. Cancer Res (2005) 1.46
The p53 gene and protein in human brain tumors. J Neuropathol Exp Neurol (1994) 1.41
Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor. Oncogene (2007) 1.40
Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma? AJNR Am J Neuroradiol (2006) 1.39
Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer (2010) 1.36
Microarray analysis of MRI-defined tissue samples in glioblastoma reveals differences in regional expression of therapeutic targets. Diagn Mol Pathol (2006) 1.34
Fractional anisotropy value by diffusion tensor magnetic resonance imaging as a predictor of cell density and proliferation activity of glioblastomas. Surg Neurol (2005) 1.34
Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathol (2010) 1.32
Angiogenesis and invasion in glioma. Brain Tumor Pathol (2011) 1.31
Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. Radiology (2010) 1.28
Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Oncogene (2001) 1.15
The role of matrix metalloproteinase genes in glioma invasion: co-dependent and interactive proteolysis. J Neurooncol (2001) 1.13
Therapeutic strategies for inhibiting invasion in glioblastoma. Expert Rev Neurother (2009) 1.13
Targeting integrins in malignant glioma. Target Oncol (2010) 1.11
Vascular gene expression patterns are conserved in primary and metastatic brain tumors. J Neurooncol (2010) 1.10
Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. AJNR Am J Neuroradiol (2000) 1.09
Chemokines and glioma: invasion and more. J Neuroimmunol (2010) 1.07
Angiogenesis and gliomas: current issues and development of surrogate markers. Neurosurgery (2008) 1.00
Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics (2009) 0.99
Proton magnetic resonance spectroscopy imaging in the study of human brain cancer. Q J Nucl Med Mol Imaging (2009) 0.95
Tumor localization of an anti-TGF-β antibody and its effects on gliomas. Int J Oncol (2011) 0.86
Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol (1998) 0.86
Expression of Matrix Metalloproteinase-26 promotes human glioma U251 cell invasion in vitro and in vivo. Oncol Rep (2010) 0.81
A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme. Br J Radiol (2011) 0.81
Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res (2007) 6.57
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A (2005) 6.54
Formation of native prions from minimal components in vitro. Proc Natl Acad Sci U S A (2007) 5.94
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
Quantitative fluorescence in intracranial tumor: implications for ALA-induced PpIX as an intraoperative biomarker. J Neurosurg (2011) 2.86
Synergistic function of E2F7 and E2F8 is essential for cell survival and embryonic development. Dev Cell (2008) 2.61
Quantitative and qualitative 5-aminolevulinic acid-induced protoporphyrin IX fluorescence in skull base meningiomas. Neurosurg Focus (2011) 2.22
Long-term seizure, cognitive, and psychiatric outcome following trans-middle temporal gyrus amygdalohippocampectomy and standard temporal lobectomy. J Neurosurg (2013) 2.04
Reactivity assays, substances, samples and in vitro alternatives: why should we care? Contact Dermatitis (2009) 1.93
Multifactor dimensionality reduction for graphics processing units enables genome-wide testing of epistasis in sporadic ALS. Bioinformatics (2010) 1.76
Cancer stem cells are enriched in the side population cells in a mouse model of glioma. Cancer Res (2008) 1.75
Selective incorporation of polyanionic molecules into hamster prions. J Biol Chem (2007) 1.71
A role for Id2 in regulating photic entrainment of the mammalian circadian system. Curr Biol (2009) 1.70
Stereopsis-guided brain shift compensation. IEEE Trans Med Imaging (2005) 1.62
Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging (2002) 1.59
The Professional Athlete Spine Initiative: outcomes after lumbar disc herniation in 342 elite professional athletes. Spine J (2011) 1.58
Genetic determinants of malignancy in a mouse model for oligodendroglioma. Cancer Res (2003) 1.46
Id4 regulates neural progenitor proliferation and differentiation in vivo. Development (2004) 1.45
Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model. ASN Neuro (2011) 1.44
Hippocampal interictal epileptiform activity disrupts cognition in humans. Neurology (2013) 1.44
In vivo quantification of retraction deformation modeling for updated image-guidance during neurosurgery. IEEE Trans Biomed Eng (2002) 1.38
Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. Neuro Oncol (2011) 1.38
Dopamine efflux in the rat striatum evoked by electrical stimulation of the subthalamic nucleus: potential mechanism of action in Parkinson's disease. Eur J Neurosci (2006) 1.38
Prion protein glycosylation is not required for strain-specific neurotropism. J Virol (2009) 1.31
Estimation of brain deformation for volumetric image updating in protoporphyrin IX fluorescence-guided resection. Stereotact Funct Neurosurg (2009) 1.30
Review of Neurosurgical Fluorescence Imaging Methodologies. IEEE J Sel Top Quantum Electron (2010) 1.29
Oncogenic regulators and substrates of the anaphase promoting complex/cyclosome are frequently overexpressed in malignant tumors. Am J Pathol (2007) 1.28
Mutual-information-based image to patient re-registration using intraoperative ultrasound in image-guided neurosurgery. Med Phys (2008) 1.27
Cortical surface tracking using a stereoscopic operating microscope. Neurosurgery (2005) 1.24
ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci U S A (2010) 1.23
Combined fluorescence and reflectance spectroscopy for in vivo quantification of cancer biomarkers in low- and high-grade glioma surgery. J Biomed Opt (2011) 1.23
A boundary element approach for image-guided near-infrared absorption and scatter estimation. Med Phys (2007) 1.22
Assimilating intraoperative data with brain shift modeling using the adjoint equations. Med Image Anal (2005) 1.22
Induction of astrocyte differentiation by propentofylline increases glutamate transporter expression in vitro: heterogeneity of the quiescent phenotype. Glia (2006) 1.21
Trans-dominant inhibition of prion propagation in vitro is not mediated by an accessory cofactor. PLoS Pathog (2009) 1.21
Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer (2009) 1.20
Neurotransmitter release from high-frequency stimulation of the subthalamic nucleus. J Neurosurg (2004) 1.19
High-frequency stimulation of the subthalamic nucleus increases glutamate in the subthalamic nucleus of rats as demonstrated by in vivo enzyme-linked glutamate sensor. Brain Res (2007) 1.18
Maximum principal strain and strain rate associated with concussion diagnosis correlates with changes in corpus callosum white matter indices. Ann Biomed Eng (2011) 1.18
Atypical teratoid/rhabdoid tumor of the spine in an adult: case report and review of the literature. J Neurooncol (2007) 1.18
Quantitative, spectrally-resolved intraoperative fluorescence imaging. Sci Rep (2012) 1.17
Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology (2007) 1.16
Postoperative stereotactic radiosurgery without whole-brain radiation therapy for brain metastases: potential role of preoperative tumor size. Int J Radiat Oncol Biol Phys (2012) 1.16
Deep brain stimulation results in local glutamate and adenosine release: investigation into the role of astrocytes. Neurosurgery (2010) 1.15
Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis. J Neuroinflammation (2010) 1.13
A novel mouse model of Niemann-Pick type C disease carrying a D1005G-Npc1 mutation comparable to commonly observed human mutations. Hum Mol Genet (2011) 1.10
Variation partitioning involving orthogonal spatial eigenfunction submodels. Ecology (2012) 1.07
Current and future clinical applications for optical imaging of cancer: from intraoperative surgical guidance to cancer screening. Semin Oncol (2011) 1.07
Outcome of frontal lobe epilepsy surgery. Epilepsia (2012) 1.06
The effects of prion protein proteolysis and disaggregation on the strain properties of hamster scrapie. J Gen Virol (2008) 1.05
Data-guided brain deformation modeling: evaluation of a 3-D adjoint inversion method in porcine studies. IEEE Trans Biomed Eng (2006) 1.04
Displacement estimation with co-registered ultrasound for image guided neurosurgery: a quantitative in vivo porcine study. IEEE Trans Med Imaging (2003) 1.04
Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res (2002) 1.03
Pulsed-light imaging for fluorescence guided surgery under normal room lighting. Opt Lett (2013) 1.02
A cluster of amyotrophic lateral sclerosis in New Hampshire: a possible role for toxic cyanobacteria blooms. Amyotroph Lateral Scler (2009) 1.02
ID2 (inhibitor of DNA binding 2) is a rhythmically expressed transcriptional repressor required for circadian clock output in mouse liver. J Biol Chem (2009) 1.01
5-Aminolevulinic acid-induced protoporphyrin IX fluorescence in meningioma: qualitative and quantitative measurements in vivo. Neurosurgery (2014) 1.01
Preliminary assessment of a neuropathic pain treatment and referral algorithm for patients with cancer. J Pain Symptom Manage (2011) 1.01
Spatial frequency domain tomography of protoporphyrin IX fluorescence in preclinical glioma models. J Biomed Opt (2012) 1.00
Model-Updated Image-Guided Neurosurgery Using the Finite Element Method: Incorporation of the Falx Cerebri. Med Image Comput Comput Assist Interv (1999) 0.99
Data assimilation using a gradient descent method for estimation of intraoperative brain deformation. Med Image Anal (2009) 0.99
Propionic acidemia: a neuropathology case report and review of prior cases. Arch Pathol Lab Med (2003) 0.99
Deep brain stimulation of the nucleus accumbens reduces alcohol intake in alcohol-preferring rats. Neurosurg Focus (2010) 0.99
In situ photodegradation of incorporated polyanion does not alter prion infectivity. PLoS Pathog (2011) 0.97
Id2 is required for specification of dopaminergic neurons during adult olfactory neurogenesis. J Neurosci (2008) 0.96
Cortical surface strain estimation using stereovision. Med Image Comput Comput Assist Interv (2011) 0.96
Scaled cortical impact in immature swine: effect of age and gender on lesion volume. J Neurotrauma (2009) 0.96
Defining the toxic mode of action of ester sulphonates using the joint toxicity of mixtures. Chemosphere (2006) 0.96
A head holder for magnetic resonance imaging that allows the stereotaxic alignment of spontaneously occurring intracranial mouse tumors. J Neurosci Methods (2002) 0.96
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol (2013) 0.96
Imaging the shear modulus of the heel fat pads. Clin Biomech (Bristol, Avon) (2005) 0.96
Measurement and estimation of electrophilic reactivity for predictive toxicology. Chem Rev (2011) 0.96
Glioblastoma multiforme treatment with clinical trials for surgical resection (aminolevulinic acid). Neurosurg Clin N Am (2012) 0.96
Abolition of spindle oscillations and 3-Hz absence seizurelike activity in the thalamus by using high-frequency stimulation: potential mechanism of action. J Neurosurg (2005) 0.95
Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum Pathol (2006) 0.94
Mechanistic applicability domains for nonanimal-based prediction of toxicological end points: general principles and application to reactive toxicity. Chem Res Toxicol (2006) 0.94
Inhibitor of DNA binding 4 (ID4) regulation of adipocyte differentiation and adipose tissue formation in mice. J Biol Chem (2010) 0.94
Exploratory Visual Analysis of statistical results from microarray experiments comparing high and low grade glioma. Cancer Inform (2007) 0.93
System and methods for wide-field quantitative fluorescence imaging during neurosurgery. Opt Lett (2013) 0.93
Immunotherapy for the treatment of glioblastoma. Cancer J (2012) 0.93
Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph Lateral Scler (2009) 0.93
Confocal microscopy for the histological fluorescence pattern of a recurrent atypical meningioma: case report. Neurosurgery (2011) 0.92